OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care Bellevue, Washington & Seoul, South Korea

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer

in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Bellevue, Washington & Seoul, South Korea - October 14, 2025

- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"),

a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication

to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose

monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

Through this acquisition, OSRH aims to strengthen its medical-device

platform, diversify its healthcare portfolio, and capture recurring revenue from the global glucose-monitoring market. Strategic highlights

of the WORIO acquisition include:

Under the definitive agreement, WORIO will become a wholly owned subsidiary

of OSRH's Korean affiliate, OSR Holdings Co., Ltd. ("OSRK"). WORIO shareholders will receive newly issued OSRK shares

worth KRW15bn (~$10.5 million) in exchange for WORIO shares. If, within 3 years of the share exchange, OSRH reaches at least $10 per share,

OSRK shares may be converted into OSRH common stock at a ratio of 12.96:1 or approximately 1.09 million new shares.

"The acquisition of Woori IO delivers significant upside for

OSRH shareholders," said Peter Hwang, CEO of OSRH. "Acquired at a valuation of less than $11 million, Woori IO is an undervalued

opportunity compared with multi-billion-dollar continuous glucose monitor (CGM) peers like Dexcom. We believe WORIO brings a recognized,

high-growth noninvasive glucose-monitoring platform into the OSRH ecosystem. Importantly, there is no immediate dilution for OSRH shareholders,

allowing them to participate in the potential upside from a disruptive technology well-positioned to enter the fast-growing global glucose-monitoring

market while preserving existing ownership stakes."

"We're thrilled to become an OSR Company, a major milestone

for Woori IO" said Sunkie Park, CEO of WORIO. "We have full confidence in OSR Holdings' global expertise to not only

help us develop and scale our needle-free glucose monitoring solution for diabetes care but also explore additional use cases and broader

digital health initiatives, maximizing the impact of our proprietary NIRS-based technology for patients and healthcare providers worldwide."

WORIO has partnered with a major global consumer electronics company

to advance the clinical development of its noninvasive glucose-monitoring devices. The collaboration included non-dilutive funding and

participation of the partner's employees in initial proof-of-concept trials. WORIO's regulatory strategy includes launching

its clinical trials in Korea at a leading medical center in Seoul, utilizing the center's deep domain expertise to advance studies

and generate data that can potentially support approvals for medical devices regionally.

Following the acquisition, WORIO will leverage OSRH's governance,

global partnerships and clinical development resources to accelerate product development, enhance supply readiness, and boost commercialization

speed and efficiency. "This technology could redefine glucose monitoring for millions living with diabetes," said Dr. Constance

H fer, CSO of OSRH. "By enabling continuous, truly needle-free data collection, it also supports deeper research into metabolic

health, cancer recurrence, exercise physiology, and human performance."

Forward-Looking Statements

This press release includes forward-looking statements regarding the

expected benefits, synergies, timing, and operations related to this acquisition. Actual results may differ materially due to risks and

uncertainties, including regulatory approvals, market conditions, integration execution, and other transaction-related contingencies.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company

dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology,

regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve

global health outcomes. Learn more at www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a South Korea-based medical device company developing noninvasive

biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking

and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's

startup program for its innovation in NIGM technology.

Media & Investor Contacts

Email: ir@osr-holdings.com